These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
876 related articles for article (PubMed ID: 31339850)
21. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474 [TBL] [Abstract][Full Text] [Related]
22. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997 [TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795 [TBL] [Abstract][Full Text] [Related]
24. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients. Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355 [TBL] [Abstract][Full Text] [Related]
25. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid. Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598 [TBL] [Abstract][Full Text] [Related]
26. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients]. Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677 [No Abstract] [Full Text] [Related]
27. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711 [TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy for Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810 [No Abstract] [Full Text] [Related]
29. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992 [TBL] [Abstract][Full Text] [Related]
30. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791 [TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318 [TBL] [Abstract][Full Text] [Related]
32. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Li W; Qiu T; Guo L; Ying J Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013 [TBL] [Abstract][Full Text] [Related]
33. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR. Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157 [TBL] [Abstract][Full Text] [Related]
34. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040 [TBL] [Abstract][Full Text] [Related]